HONG KONG – Shanghai-based biopharmaceutical firm Harbour Biomed Therapeutics Ltd. completed a series B financing of $85 million, "slightly above" its target, with the round led by Singapore's wealth fund GIC Private Ltd. Harbour anticipates more fundraising in 2019.
